Cost-effectiveness simulation model of abatacept versus anti-TNF treatment strategies in rheumatoid arthritis in France

被引：0
|
作者：
Saraux, Alain [1 ]
Goupille, Philippe [2 ]
Gossec, Laure [3 ]
Bregman, Bruno [4 ]
Boccard, Eric [4 ]
Dupont, Danielle [5 ]
Beresmak, Ariel [6 ,7 ]
机构：
[1] Hop Cavale Blanche, Brest, France
[2] Univ Tours, CHRU Tours, Serv Rhumatol, Tours, France
[3] Cochin Hosp, Rheumatol B Dept, Paris, France
[4] Bristol Myers Squibb Co, Rueil Malmaison, France
[5] Bristol Myers Squibb Co, Int Corp, Braine Lalleud, Belgium
[6] Univ Paris 05, LIRAES, Paris, France
[7] Data Mining Int, Geneva, Switzerland
来源：
ARTHRITIS AND RHEUMATISM | 2008年 / 58卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
797
引用
收藏
页码：S463 / S463
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis
    Tsao, Nicole W.
    Shojania, Kam
    Marra, Carlo A.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (01) : 9 - 18
  • [22] ABATACEPT OR INFLIXIMAB FOR RHEUMATOID ARTHRITIS IN VENEZUELA? A COST-EFFECTIVENESS ANALYSIS
    Alfonso-Cristancho, R.
    Serra, N.
    Aiello, E. C.
    Roa, C. N.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A126 - A127
  • [23] EFFICACY AND COST EFFECTIVENESS OF ANTI-TNF DRUGS FOR REUMATOID ARTHRITIS TREATMENT
    Alvarez Alejandro, Gonzalez
    Barrera Manuel, Gomez
    Blasco Joaquin, Borras
    Emilio Jose, Giner Serret
    [J]. ATENCION FARMACEUTICA, 2013, 15 (04): : 244 - +
  • [24] CLINICAL EFFECTIVENESS AND INFECTION RATE IN RHEUMATOID ARTHRITIS PATIENTS SWITCHED FROM ANTI-TNF AGENTS TO ABATACEPT
    Pietrosanti, M.
    Di Rosa, R.
    Salemi, S.
    Markovic, M.
    Carusi, V.
    Biondo, M. I.
    Catoni, M.
    Lagana, B.
    Sorgi, M. L.
    D'Amelio, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 888 - 888
  • [25] Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany
    Beresniak, A.
    Baerwald, C.
    Zeidler, H.
    Kruger, K.
    Neubauer, A. S.
    Dupont, D.
    Merkesdal, S.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (03) : 400 - 408
  • [26] Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review
    Martelli, Laura
    Olivera, Pablo
    Roblin, Xavier
    Attar, Alain
    Peyrin-Biroulet, Laurent
    [J]. JOURNAL OF GASTROENTEROLOGY, 2017, 52 (01) : 19 - 25
  • [27] Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review
    Laura Martelli
    Pablo Olivera
    Xavier Roblin
    Alain Attar
    Laurent Peyrin-Biroulet
    [J]. Journal of Gastroenterology, 2017, 52 : 19 - 25
  • [28] COST-EFFECTIVENESS OF USE OF ETANERCEPT VS THE ANTI-TNF MONOCLONAL ANTIBODY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN COSTA RICA
    Aguirre, A.
    Garcia, E.
    Bierschwale, H.
    Prado, M.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A522 - A522
  • [29] Cost-effectiveness of TNF-α-blocking agents in the treatment of rheumatoid arthritis
    Merkesdal, S
    Ruof, J
    Mittendorf, T
    Zeidler, H
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (09) : 1881 - 1886
  • [30] Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept
    Neubauer, A. S.
    Minartz, C.
    Herrmann, K. H.
    Baerwald, C. G. O.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (03) : 448 - 454
12345